Human Papilloma Virus (HPV) Vaccine
Overview
The HPV vaccines work like other immunizations that guard against viral infection. The investigators hypothesized that the unique surface components of HPV might create an antibody response that is capable of protecting the body against infection and that these components could be used to form the basis of a vaccine. These surface components can interact with one another to form virus-like particles (VLP) that are noninfectious and stimulate the immune system to produce antibodies that can prevent the complete papillomavirus from infecting cells.
Primary Characterstics
Indications
Back to top
Pharmacokinetics
Back to top
Contraindications
Back to top
Back to top
Side Effects
Back to top
Dosage
Human Papilloma Virus (HPV) Vaccine's dosage details are as follows:
| Dose
|
Single Dose
|
Frequency
|
Route
|
Instructions
|
Adult Dosage
|
| 0.5 mL | 0.5 (0.5) | As recommended. | IM | Between 10 to 25 years for prevention of cervical cancer. |
| 0.5 mL | 0.5 (0.5) | As recommended. | IM | Usual Adult Dose for Human Papillomavirus Prophylaxis: Repeat dose in 2 months and 6 months for a total of 3 doses. (Between 9 to 26 years) |
Paedriatic Dosage (20kg)
|
| No data regarding the Paedriatic dosage details of Human Papilloma Virus (HPV) Vaccine is available. |
Neonatal Dosage (3kg)
|
| No data regarding the neonatal dosage details of Human Papilloma Virus (HPV) Vaccine is available. |
High Risk Groups
Back to top
Warning / Precautions
Back to top
Storage Conditions
Back to top
Interference in Pathology
Back to top
Brands / Trade Names of
Human Papilloma Virus (HPV) Vaccine
Back to top
Manufacturers of
Human Papilloma Virus (HPV) Vaccine
in Pakistan
Back to top
Previous Drug Generic - Next Drug Generic